ONWARD ARC-EX®: A Game-Changer in Spinal Cord Injury Therapy

ONWARD Medical N.V. (Euronext: ONWD) has made headlines with the recognition of its innovative ARC-EX® System as one of TIME's Best Inventions of 2024. This groundbreaking technology, designed to restore movement, function, and independence in people with spinal cord injury (SCI), has garnered significant attention for its potential to transform lives. In this article, we explore the implications of this recognition for ONWARD Medical, the ARC-EX System's potential impact on the lives of millions, and its alignment with TIME's focus on growing fields like healthcare and AI.

The ARC-EX System's selection by TIME highlights its innovative use of non-invasive spinal cord stimulation, as demonstrated in the Up-LIFT trial. This breakthrough technology targets the spinal cord non-invasively, aiding functional recovery and reducing the need for caregiver assistance. The system's potential to restore independence in daily activities and improve quality of life for millions of people with SCI was a key factor in its recognition.

The Up-LIFT trial's positive results significantly influenced TIME's decision to include the ARC-EX System in its list of best inventions. The trial demonstrated significant improvements in upper limb strength, function, and sensation in people with chronic tetraplegia due to cervical SCI. With 90% of participants experiencing improved strength or function, and 87% reporting improvements in overall quality of life, the ARC-EX System's potential to transform lives was undeniable.


The ARC-EX System's recognition by TIME arrives as ONWARD Medical awaits regulatory approval for the ARC-EX System in the US. This positive media attention may expedite the FDA's review process, as it highlights the system's potential to transform lives. Moreover, the recognition could accelerate market adoption post-launch, as consumers and healthcare providers become more aware of the innovative therapy.

The ARC-EX System's alignment with TIME's focus on growing fields, such as healthcare and AI, further emphasizes its significance. The system's innovative, non-invasive spinal cord stimulation therapy addresses a critical need in the SCI community, offering hope for improved upper limb function and quality of life. This breakthrough in neurotechnology, developed by ONWARD Medical, showcases the potential of AI-driven medical advancements to transform lives and aligns with TIME's recognition of extraordinary innovations changing lives.


In conclusion, the ARC-EX System's recognition as one of TIME's Best Inventions of 2024 underscores its potential to revolutionize spinal cord injury therapy. With its innovative use of non-invasive spinal cord stimulation and proven results in the Up-LIFT trial, the ARC-EX System offers hope for millions of people with SCI. As ONWARD Medical awaits regulatory approval, investors should keep a close eye on this promising technology and its potential to transform lives and generate returns.